Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Months after cancer drug trial, Merus agrees to be bought at 41% premium

Genmab to buy Dutch cancer drugmaker Merus for $8 billion